Alpine Immune Sciences(ALPN) - 2020 Q3 - Quarterly Report

Financial Performance - The company reported a net loss of $6.1 million for Q3 2020, compared to a net loss of $11.5 million for Q3 2019, and a total net loss of $21.6 million for the nine months ended September 30, 2020, down from $35.7 million for the same period in 2019[52]. - Net loss for Q3 2020 was $6.1 million, improved from a net loss of $11.5 million in Q3 2019, representing a reduction of 46.5%[67]. - The company has incurred operating losses since inception and anticipates continuing net losses in the long term[81]. Cash and Investments - As of September 30, 2020, the company had cash, cash equivalents, restricted cash, and short-term investments totaling $141.3 million[51]. - Net cash provided by operating activities was $39.4 million for the nine months ended September 30, 2020, primarily due to a $60.0 million upfront payment from AbbVie[86]. - Net cash provided by investing activities was $24.0 million during the nine months ended September 30, 2020, reflecting net purchases and maturities of short-term investments[87]. - Net cash provided by financing activities was $61.4 million for the nine months ended September 30, 2020, mainly from the sale of approximately 5.9 million units under the July 2020 Securities Purchase Agreement[88]. Revenue and Collaboration Agreements - The company entered into an agreement with AbbVie in June 2020, receiving a nonrefundable upfront payment of $60.0 million and potential milestone payments totaling up to $450.0 million[54]. - Revenue recognized from the AbbVie Agreement was $1.6 million for the three and nine months ended September 30, 2020, with a remaining deferred revenue balance of $58.4 million[55]. - Under the Adaptimmune Collaboration Agreement, the company recognized revenue of $356,000 for Q3 2020 and $2.0 million for the nine months ended September 30, 2020[55]. - Collaboration revenue for Q3 2020 was $1.9 million, an increase of $1.6 million compared to $0.3 million in Q3 2019[68]. - Collaboration revenue for the nine months ended September 30, 2020, was $3.7 million, an increase of $2.8 million compared to $0.9 million in the same period of 2019[77]. Research and Development - The company plans to initiate a Phase 2 study for ALPN-101 in adults with lupus in the first half of 2021[51]. - The lead oncology program, ALPN-202, is currently in a Phase 1 study, with updates expected in the first half of 2021[51]. - The company is conducting additional nonclinical studies for ALPN-303, aiming to enable clinical trials by the end of 2021[51]. - Research and development expenses for Q3 2020 were $6.2 million, down from $9.5 million in Q3 2019, a decrease of 34.5%[57]. - Research and development expenses for the nine months ended September 30, 2020, were $18.1 million, down from $30.0 million in the same period of 2019, a decrease of 39.6%[74]. Operating Expenses - Total operating expenses for Q3 2020 were $8.9 million, compared to $12.0 million in Q3 2019, reflecting a decrease of 26%[67]. - Total operating expenses for the nine months ended September 30, 2020, were $26.0 million, compared to $37.4 million in the same period of 2019, a decrease of 30.6%[77]. - General and administrative expenses for Q3 2020 were $2.7 million, an increase of 10.6% from $2.5 million in Q3 2019[67]. Future Outlook - The company expects to incur significant expenses and operating losses for several years as it continues clinical trials and research and development efforts[52]. - The company expects to continue incurring significant expenses and operating losses as it advances its research and development programs[80]. - The company intends to finance its cash needs through a combination of equity or debt financings and collaboration agreements[80]. - The company has no committed external sources of capital beyond milestone payments from collaborators, which may affect its ability to fund operations[81].